Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.67 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.67 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.67 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.58 |
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26185807 | 1.00 | CRBN (0.67) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL31434511 | 0.94 | CRBN (0.65) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL26185796 | 0.94 | CRBN (0.67) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL30623185 | 0.94 | CRBN (0.67) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL31216404 | 0.93 | CRBN (0.64) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL26185802 | 0.93 | CRBN (0.66) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL30608822 | 0.93 | CRBN (0.63) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL26185800 | 0.93 | CRBN (0.63) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| Hydrochloric Acid SCHEMBL31434497 | 0.92 | CRBN (0.65) | CRBNDDB1GSPT1IKZF3CSNK1A1 | |
| SCHEMBL31434463 | 0.92 | CRBN (0.67) | CRBNDDB1GSPT1IKZF3CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4508044-A1 | NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | Bristol-Myers Squibb Company (US) | 2025-02-19 | — | — | EP | claimed |
| CN-119013266-A | Novel GSPT compounds and methods of use of novel compounds | 百时美施贵宝公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2023201282-A1 | NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-19 | — | — | WO | claimed |
| US-20250092012-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2025-03-20 | — | — | US | disclosed |
| EP-4508044-A1 | NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | Bristol-Myers Squibb Company (US) | 2025-02-19 | — | — | EP | disclosed |
| US-12187699-B2 | GSPT1 compounds and methods of use of the novel compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-07 | — | — | US | disclosed |
| CN-119013266-A | Novel GSPT compounds and methods of use of novel compounds | 百时美施贵宝公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20230331693-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2023-10-19 | — | — | US | disclosed |
| WO-2023201282-A1 | NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331693-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | GSPT1, GSS, GSPT2 | CRBN 3671/4885DDB1 994/4885GSPT1 1/4885 |
| US-20250092012-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | GSPT1, GSS, GSPT2 | CRBN 3671/4885DDB1 994/4885GSPT1 1/4885 |
| US-12187699-B2 | GSPT1 compounds and methods of use of the novel compounds | GSPT1, GSS, GSPT2 | CRBN 3671/4885DDB1 994/4885GSPT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.